Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
3,585
Views
21
CrossRef citations to date
0
Altmetric
Original Research

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers

Kwang-Yu Changa Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;b National Institute of Cancer Research, National Health Research Institutes, Tainan, TaiwanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5240-2760View further author information
ORCID Icon,
Nai-Jung Chianga Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;b National Institute of Cancer Research, National Health Research Institutes, Tainan, TaiwanView further author information
,
Shang-Yin Wua Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, TaiwanView further author information
,
Chia-Jui Yena Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, TaiwanView further author information
,
Shang-Hung Chena Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;b National Institute of Cancer Research, National Health Research Institutes, Tainan, TaiwanView further author information
,
Yu-Min Yeha Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, TaiwanView further author information
,
Chien-Feng Lic Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan;b National Institute of Cancer Research, National Health Research Institutes, Tainan, TaiwanView further author information
,
Xiaoxing Fengd Polaris Pharmaceuticals, Inc., San Diego, California, USAView further author information
,
Katherine Wud Polaris Pharmaceuticals, Inc., San Diego, California, USAView further author information
,
Amanda Johnstond Polaris Pharmaceuticals, Inc., San Diego, California, USAView further author information
,
John S. Bomalaskid Polaris Pharmaceuticals, Inc., San Diego, California, USAView further author information
,
Bor-Wen Wud Polaris Pharmaceuticals, Inc., San Diego, California, USAView further author information
,
Jianjun Gaoe Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Sumit K. Subudhie Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Ahmed O. Kasebf Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Jorge M. Blandog The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TXUSAView further author information
,
Shalini S. Yadavg The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TXUSAView further author information
,
Peter W. Szlosarekh Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, UKView further author information
&
Li-Tzong Cheni Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;a Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;b National Institute of Cancer Research, National Health Research Institutes, Tainan, TaiwanCorrespondence[email protected]
View further author information
 show all
Article: 1943253 | Received 16 Feb 2021, Accepted 11 Jun 2021, Published online: 12 Jul 2021

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Joséphine Carpentier, Iuliia Pavlyk, Uma Mukherjee, Peter E Hall & Peter W Szlosarek. (2022) Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy. Lung Cancer: Targets and Therapy 13, pages 53-66.
Read now
Byung Woog Kang & Ian Chau. (2021) Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. Expert Opinion on Investigational Drugs 30:11, pages 1089-1107.
Read now

Articles from other publishers (19)

Emma Hajaj, Sabina Pozzi & Ayelet Erez. (2024) From the Inside Out: Exposing the Roles of Urea Cycle Enzymes in Tumors and Their Micro and Macro Environments. Cold Spring Harbor Perspectives in Medicine 14:4, pages a041538.
Crossref
Peter W. Szlosarek, Benjamin C. Creelan, Thomas Sarkodie, Luke Nolan, Paul Taylor, Olga Olevsky, Federica Grosso, Diego Cortinovis, Meenali Chitnis, Amy Roy, David Gilligan, Hedy Kindler, Dionysis Papadatos-Pastos, Giovanni L. Ceresoli, Aaron S. Mansfield, Anne Tsao, Kenneth J. O’Byrne, Anna K. Nowak, Jeremy Steele, Michael Sheaff, Chiung-Fang Shiu, Chih-Ling Kuo, Amanda Johnston, John Bomalaski, Marjorie G. Zauderer, Dean A. Fennell, Igor I. Rybkin, Christian D. Rolfo, Melanie MacKean, Nicola Steele, Kevin Franks, Paul Shaw, Michael J. Lind, Sunil Upadhyay, Thomas John, Christos Karapetis, Ratnesh Srivastav, Manlio Mencoboni, Antonio Chella, Nicoletta Zilembo, Filippo de Marinis, Maria Giulia Stella, Inn-Wen Chong & Chin-Chou Wang. (2024) Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma. JAMA Oncology 10:4, pages 475.
Crossref
Rafał Jastrząb, Rafał Tomecki, Aneta Jurkiewicz, Damian Graczyk, Agnieszka K. Szczepankowska, Jennifer Mytych, Damian Wolman & Pawel Siedlecki. (2024) The strain-dependent cytostatic activity of Lactococcus lactis on CRC cell lines is mediated through the release of arginine deiminase. Microbial Cell Factories 23:1.
Crossref
Shijing You, Xiahui Han, Yuance Xu & Qin Yao. (2023) Research progress on the role of cationic amino acid transporter (CAT) family members in malignant tumors and immune microenvironment. Amino Acids 55:10, pages 1213-1222.
Crossref
Zhe-Nan Ling, Yi-Fan Jiang, Jun-Nan Ru, Jia-Hua Lu, Bo Ding & Jian Wu. (2023) Amino acid metabolism in health and disease. Signal Transduction and Targeted Therapy 8:1.
Crossref
Christina M. Vidal, Ching Ouyang, Yue Qi, Carlos Mendez-Dorantes, Alaysia Coblentz, Jackelyn A. Alva-Ornelas, Jeremy M. Stark, Victoria L. Seewaldt & David K. Ann. (2023) Arginine regulates HSPA5/BiP translation through ribosome pausing in triple-negative breast cancer cells. British Journal of Cancer 129:3, pages 444-454.
Crossref
Leonard C. Rogers, Jeff C. Kremer, Caitlyn B. Brashears, Zongtao Lin, Zhixian Hu, Alliny C.S. Bastos, Adriana Baker, Nicole Fettig, Dong Zhou, Kooresh I. Shoghi, Carina A. Dehner, John S.A. Chrisinger, John S. Bomalaski, Benjamin A. Garcia, Toshinao Oyama, Eileen P. White & Brian A. Van Tine. (2023) Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment. Clinical Cancer Research 29:16, pages 3189-3202.
Crossref
Yu-De Chu, Ming-Wei Lai & Chau-Ting Yeh. (2023) Unlocking the Potential of Arginine Deprivation Therapy: Recent Breakthroughs and Promising Future for Cancer Treatment. International Journal of Molecular Sciences 24:13, pages 10668.
Crossref
Charlotte Linke, Thomas Freitag, Christin Riess, Jana Vanessa Scheffler, Katharina del Moral, Nina Schoenwaelder, Tomas Fiedler, Adina Fiebig, Philipp Kaps, Daniel Dubinski, Björn Schneider, Wendy Bergmann, Carl Friedrich Classen & Claudia Maletzki. (2023) The addition of arginine deiminase potentiates Mithramycin A-induced cell death in patient-derived glioblastoma cells via ATF4 and cytochrome C. Cancer Cell International 23:1.
Crossref
George C. Field, Iuliia Pavlyk & Peter W. Szlosarek. (2023) Bench-to-Bedside Studies of Arginine Deprivation in Cancer. Molecules 28:5, pages 2150.
Crossref
Yu-De Chu, Hui-Fen Liu, Yi-Chen Chen, Chun-Hung Chou & Chau-Ting Yeh. (2022) WWOX-rs13338697 genotype predicts therapeutic efficacy of ADI-PEG 20 for patients with advanced hepatocellular carcinoma. Frontiers in Oncology 12.
Crossref
Yu Ping, Chunyi Shen, Bo Huang & Yi Zhang. (2022) Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity. Cells 11:19, pages 3103.
Crossref
Naihui Sun & Xing Zhao. (2022) Argininosuccinate synthase 1, arginine deprivation therapy and cancer management. Frontiers in Pharmacology 13.
Crossref
Pui Ying Chan, Melissa M. Phillips, Stephen Ellis, Amanda Johnston, Xiaoxing Feng, Amit Arora, Gordon Hay, Victoria M. L. Cohen, Mandeep S. Sagoo, John S. Bomalaski, Michael T. Sheaff & Peter W. Szlosarek. (2022) A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma . Pigment Cell & Melanoma Research 35:4, pages 461-470.
Crossref
Lukas Kraehenbuehl, Aliya Holland, Emma Armstrong, Sirinya O’Shea, Levi Mangarin, Sara Chekalil, Amanda Johnston, John S. Bomalaski, Joseph P. Erinjeri, Christopher A. Barker, Jasmine H. Francis, Jedd D. Wolchok, Taha Merghoub & Alexander N. Shoushtari. (2022) Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. Cancers 14:11, pages 2638.
Crossref
Rico Schwarz, Eric Zitzow, Adina Fiebig, Silvio Hering, Yvonne Humboldt, Nina Schoenwaelder, Neele Kämpfer, Kerren Volkmar, Burkhard Hinz, Bernd Kreikemeyer, Claudia Maletzki & Tomas Fiedler. (2021) PEGylation increases antitumoral activity of arginine deiminase of Streptococcus pyogenes. Applied Microbiology and Biotechnology 106:1, pages 261-271.
Crossref
Racheal Johnson, Michele Cummings, Amudha Thangavelu, Georgios Theophilou, Diederick de Jong & Nicolas Orsi. (2021) Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment. Cancers 13:24, pages 6231.
Crossref
Yaolin Xu, Lijie He, Qiang Fu & Junzhe Hu. (2021) Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints. Frontiers in Oncology 11.
Crossref
Peter W. Szlosarek, Akhila G. Wimalasingham, Melissa M. Phillips, Peter E. Hall, Pui Ying Chan, John Conibear, Louise Lim, Sukaina Rashid, Jeremy Steele, Paula Wells, Chiung‐Fang Shiu, Chih‐Ling Kuo, Xiaoxing Feng, Amanda Johnston, John Bomalaski, Stephen Ellis, Marianne Grantham & Michael Sheaff. (2021) Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer. Cancer Medicine 10:19, pages 6642-6652.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.